Abstract
Brefeldin A (BFA) is an fungal antibiotic that induces ER stress in eukaryotic cells. Cancer stem cells (CSCs) have indefinite potential for self-renewal and the capability to drive tumorigenesis. The effects of BFA on CSCs have not been fully investigated. In this article we investigated the inhibitory effects of BFA on human lung cancer A549 and H1299 cells. Cytotoxicity toward suspension cultures has been used as a method for the preliminary screening of drugs targeting CSCs. We showed that BFA effectively reduced the survival of suspension A549 cells (EC50 =~30 ng/ml) by inducing apoptosis, and inhibited the clonogenic activity of A549 and H1299 CSCs at the same concentration range. We also demonstrated that BFA reduced the migration ability of A549 and H1299 cells. These results suggest that BFA can effectively suppress the progression of lung cancer during tumorigenesis and metastasis. The results of this study may help develop novel therapy for future treatment of lung cancer.
Keywords: Apoptosis, Brefeldin A, cancer stem cell, clonogenesis, lung cancer, migration.
Current Signal Transduction Therapy
Title:Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells
Volume: 8 Issue: 2
Author(s): Chao-Neng Tseng, Chung-Lung Cho, Tzan-Wen Chen, Chien-Chih Chiu, Hsueh-Wei Chang, Fang-Rong Chang and Yung-Fu Chang
Affiliation:
Keywords: Apoptosis, Brefeldin A, cancer stem cell, clonogenesis, lung cancer, migration.
Abstract: Brefeldin A (BFA) is an fungal antibiotic that induces ER stress in eukaryotic cells. Cancer stem cells (CSCs) have indefinite potential for self-renewal and the capability to drive tumorigenesis. The effects of BFA on CSCs have not been fully investigated. In this article we investigated the inhibitory effects of BFA on human lung cancer A549 and H1299 cells. Cytotoxicity toward suspension cultures has been used as a method for the preliminary screening of drugs targeting CSCs. We showed that BFA effectively reduced the survival of suspension A549 cells (EC50 =~30 ng/ml) by inducing apoptosis, and inhibited the clonogenic activity of A549 and H1299 CSCs at the same concentration range. We also demonstrated that BFA reduced the migration ability of A549 and H1299 cells. These results suggest that BFA can effectively suppress the progression of lung cancer during tumorigenesis and metastasis. The results of this study may help develop novel therapy for future treatment of lung cancer.
Export Options
About this article
Cite this article as:
Tseng Chao-Neng, Cho Chung-Lung, Chen Tzan-Wen, Chiu Chien-Chih, Chang Hsueh-Wei, Chang Fang-Rong and Chang Yung-Fu, Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells, Current Signal Transduction Therapy 2013; 8(2) . https://dx.doi.org/10.2174/15743624113086660005
DOI https://dx.doi.org/10.2174/15743624113086660005 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Lung Nodule Detection using Convolutional Neural Networks with Transfer Learning on CT Images
Combinatorial Chemistry & High Throughput Screening Formulation, Optimization and <i>In vitro / In vivo</i> Characterization of Spray Dried Doxorubicin Loaded Folic Acid Conjugated Gelatin Nanoparticles
Current Molecular Pharmacology Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
Current Radiopharmaceuticals Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
Current Cancer Drug Targets Podophyllotoxin: Current Perspectives
Current Bioactive Compounds PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Trends and Topics in CD133 in Pubmed From 2000 to 2015
Current Biomarkers (Discontinued) Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design Recent Kinase and Kinase Inhibitor X-ray Structures: Mechanisms of Inhibition and Selectivity Insights
Current Medicinal Chemistry Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Targeted Therapies and other Agents as First-Line Maintenance and Beyond: Particular Benefit in Pulmonary Adenocarcinoma Patients
Current Medicinal Chemistry Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Radioprotective Gene Therapy
Current Gene Therapy Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Advances in On-line Absolute Trace Gas Analysis by SIFT-MS
Current Analytical Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine